The Indonesian Food and Drug Authority (BPOM) has identified a concerning evolution in the illegal adulteration of traditional herbal medicines (Obat Bahan Alam or OBA) following the discovery of a novel chemical substance, pyrimidenafil. This finding, which represents the first instance of this specific chemical being detected in the Indonesian market, has prompted a swift regulatory crackdown and raised alarms regarding the sophisticated tactics employed by illicit manufacturers to bypass laboratory detection.
The discovery was formally announced by BPOM Head Taruna Ikrar on September 12, marking a pivotal moment in the nation’s oversight of herbal products. The presence of pyrimidenafil was confirmed in three specific products marketed for male stamina enhancement: EXIE, YUBOKKI, and DURAMAX. All three products were reportedly manufactured by PT Bintang Kupu-Kupu, based in Tangerang, a facility now under intense scrutiny by regulatory authorities.
The Nature of Pyrimidenafil and Its Pharmacological Risks
Pyrimidenafil belongs to a class of chemical compounds known as phosphodiesterase-5 (PDE5) inhibitors. While it is not a drug typically prescribed for general public use in the same manner as common medications, its mechanism of action is functionally identical to sildenafil—the active ingredient in well-known erectile dysfunction medications.
By inhibiting the PDE5 enzyme, the compound facilitates the relaxation of smooth muscles and increases blood flow to specific areas of the body, including the genitalia. While this effect provides the "stamina enhancement" claimed by the illegal products, the uncontrolled ingestion of such compounds poses severe health risks. Potential side effects include sudden drops in blood pressure, cardiovascular strain, and adverse reactions when mixed with other prescription medications, particularly those containing nitrates.
Unlike traditional pharmaceuticals, which undergo rigorous clinical trials to establish safety profiles, dosage standardization, and contraindications, herbal supplements adulterated with pyrimidenafil offer no such transparency. Consumers are essentially being subjected to "hidden" pharmacological interventions without medical supervision, which can lead to life-threatening complications.
A Sophisticated Shift in Illicit Modus Operandi
BPOM’s investigation suggests that the introduction of pyrimidenafil is not merely a random occurrence but a calculated move by manufacturers to evade detection. For years, BPOM’s surveillance and laboratory testing protocols have been optimized to identify common adulterants such as sildenafil and tadalafil. By switching to pyrimidenafil—a chemical with a different molecular structure but the same desired physiological effect—manufacturers have attempted to exploit the gap between standard testing methods and emerging synthetic analogs.
"The use of a compound that differs from the BKO (Bahan Kimia Obat or Chemical Drug Substance) commonly found in the past is suspected to be a modus operandi intended to deceive oversight and laboratory testing," stated Taruna Ikrar during the press briefing. This cat-and-mouse game highlights the increasing necessity for regulatory agencies to adopt more agile testing methodologies, including mass spectrometry and expanded chemical databases, to stay ahead of illicit chemical synthesizers.
Chronology of Enforcement and Regulatory Action
The discovery of pyrimidenafil is part of a broader, ongoing campaign by BPOM to clean up the OBA market. The regulatory timeline leading to this discovery reflects an intensified period of surveillance:
- Early 2026: BPOM initiates a nationwide audit of herbal supplements marketed for "instant" physical enhancement following reports of adverse health events among consumers.
- July 2026: BPOM intensifies its "Operation Storm" to target unlicensed health supplements, leading to the collection of hundreds of samples from both physical storefronts and e-commerce platforms.
- August 2026: Laboratory analysis confirms the presence of pyrimidenafil in the products EXIE, YUBOKKI, and DURAMAX. Simultaneously, 35 other products are flagged for containing prohibited substances such as sibutramine (a banned weight-loss agent), dexamethasone (a corticosteroid), and paracetamol.
- September 12, 2026: BPOM officially releases its findings, announces the revocation of permits for the implicated products, and initiates legal proceedings against the manufacturers involved.
Broadening the Scope of Surveillance
Beyond the three products containing pyrimidenafil, the broader findings from July 2026 underscore a systemic issue in the industry. The detection of 35 other items categorized as "Without Distribution Permit" (Tanpa Izin Edar or TIE) containing conventional BKO substances like sildenafil and sibutramine suggests that the illegal supplement industry remains robust.
The persistent presence of dexamethasone and paracetamol in these products is particularly concerning. Dexamethasone, when used without medical oversight in supplements marketed for pain relief, can cause hormonal imbalances, immune system suppression, and bone density loss. Sibutramine, banned globally due to its link to cardiovascular risks, continues to appear in "slimming" herbal teas and capsules.
Implications for Public Health and Regulatory Policy
The emergence of pyrimidenafil forces a reevaluation of how authorities define "illegal adulteration." As synthetic chemistry advances, underground labs can easily modify the side chains of known drugs to create "analog" substances that are technically not on the forbidden list until specifically identified by regulators. This creates a significant lag time in law enforcement.
In response, BPOM has announced a multi-pronged strategy to enhance its regulatory capacity:
- Technological Upgrading: Investing in advanced analytical instruments capable of identifying unknown chemical structures rather than relying solely on "target-based" testing.
- Market Surveillance: Increasing the frequency of random sampling from online marketplaces, which have become the primary distribution channels for these illicit products.
- Public Awareness Campaigns: Moving beyond mere warnings, BPOM is working to educate the public on the "Too Good To Be True" indicator. Products promising "instant" results or "magical" cures for chronic conditions are now being explicitly flagged as high-risk categories for chemical adulteration.
Consumer Guidance and Safety Protocols
BPOM urges the public to exercise extreme skepticism regarding herbal products that offer rapid improvements in physical performance or pain relief. The agency emphasizes that legitimate traditional medicine is intended to support health over a period of time, not provide instantaneous physiological alterations.
To ensure safety, consumers are advised to:
- Check the BPOM Database: Every legitimate product must have a registration number that can be verified via the official BPOM website or the BPOM mobile application.
- Scrutinize Packaging: Avoid products with vague ingredients lists or claims that seem medically implausible.
- Purchase from Authorized Outlets: While e-commerce is convenient, consumers should prioritize official brand stores or reputable pharmacies rather than third-party resellers on social media platforms.
- Report Suspicious Products: If a product’s effects seem suspiciously strong or if the packaging appears tampered with, consumers are encouraged to report it to the BPOM HaloBPOM hotline (1500533).
As the investigation continues, the regulatory crackdown on PT Bintang Kupu-Kupu and similar entities serves as a stern warning to the industry. The evolution of chemical adulteration requires not only a response from regulators but also a shift in consumer behavior. In an era where illicit laboratories are becoming increasingly sophisticated, the most effective defense remains a combination of proactive, science-led oversight and an informed, vigilant public. The discovery of pyrimidenafil is a stark reminder that the battle for consumer safety in the herbal supplement sector is far from over.
